HBr
GSK, Spero Report Major Phase 3 Win for UTI Antibiotic; Spero’s Stock Surges
GSK; Spero Therapeutics; tebipenem HBr; Phase 3 trial; UTI antibiotic; complicated urinary tract infection; PIVOT-PO trial; stock surge; clinical trial results; FDA submission